Hubei Biocause Pharmaceutical Co., Ltd. (SHE: 000627)
China
· Delayed Price · Currency is CNY 3.960
-0.410 (-9.38%)
Jan 3, 2025, 3:04 PM CST
Hubei Biocause Pharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | -771.87 | -651.76 | 274.05 | 470.71 | 580.29 | 1,776 | Upgrade
|
| Depreciation & Amortization | 152.37 | 152.37 | 147.27 | 133.94 | 63.66 | 79.17 | Upgrade
|
| Other Amortization | 12.83 | 12.83 | 19.33 | 17.27 | 15.96 | 12.25 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.95 | -0.95 | -0.42 | 0.43 | 0.31 | -1.59 | Upgrade
|
| Gain (Loss) on Sale of Investments | -6,016 | -6,016 | -9,815 | -10,236 | -9,834 | -10,525 | Upgrade
|
| Change in Accounts Receivable | -130.2 | -130.2 | 1,642 | -609.08 | -279.52 | 1,549 | Upgrade
|
| Change in Deferred Taxes | -618.2 | -618.2 | -308.1 | -949.97 | 304.03 | 12.99 | Upgrade
|
| Change in Other Net Operating Assets | 17,485 | 17,485 | 15,018 | 13,022 | 30,512 | 33,622 | Upgrade
|
| Other Operating Activities | -33,387 | 148.99 | 842.12 | 907.23 | 714.89 | 1,243 | Upgrade
|
| Operating Cash Flow | -24,122 | 9,534 | 7,524 | 4,173 | 21,421 | 28,600 | Upgrade
|
| Operating Cash Flow Growth | - | 26.71% | 80.32% | -80.52% | -25.10% | 90.90% | Upgrade
|
| Capital Expenditures | -68.25 | -67.53 | -135.06 | -287.13 | -319.51 | -717.1 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.99 | 1.62 | 0.22 | 1.79 | 1.58 | 80.52 | Upgrade
|
| Cash Acquisitions | - | - | - | - | -3,440 | - | Upgrade
|
| Investment in Securities | 9,997 | -7,244 | -23,027 | -24,234 | -12,863 | -44,058 | Upgrade
|
| Other Investing Activities | 5,764 | 3,834 | 7,569 | 9,196 | 9,151 | 9,218 | Upgrade
|
| Investing Cash Flow | 15,458 | -3,642 | -15,615 | -15,385 | -7,682 | -35,044 | Upgrade
|
| Short-Term Debt Issued | - | - | 11,764 | 4,842 | - | 1,569 | Upgrade
|
| Long-Term Debt Issued | - | 312.56 | 694.22 | 3,132 | 2,450 | - | Upgrade
|
| Total Debt Issued | 312.56 | 312.56 | 12,458 | 7,974 | 2,450 | 1,569 | Upgrade
|
| Total Debt Repaid | -8,090 | -2,996 | -51.51 | -72.8 | -1,596 | -102.75 | Upgrade
|
| Net Debt Issued (Repaid) | -7,778 | -2,683 | 12,407 | 7,901 | 854.07 | 1,466 | Upgrade
|
| Common Dividends Paid | -749.93 | -1,413 | -699.42 | -381.32 | -633.98 | -242.12 | Upgrade
|
| Other Financing Activities | -100.93 | 20 | -629.29 | 100.62 | -47.49 | -98.6 | Upgrade
|
| Financing Cash Flow | -8,628 | -4,076 | 11,078 | 7,621 | 172.59 | 1,125 | Upgrade
|
| Foreign Exchange Rate Adjustments | -11.14 | 20.47 | 72.02 | -15.2 | -33.9 | -1.36 | Upgrade
|
| Net Cash Flow | -17,303 | 1,836 | 3,059 | -3,607 | 13,878 | -5,321 | Upgrade
|
| Free Cash Flow | -24,190 | 9,467 | 7,389 | 3,885 | 21,102 | 27,882 | Upgrade
|
| Free Cash Flow Growth | - | 28.12% | 90.17% | -81.59% | -24.32% | 89.59% | Upgrade
|
| Free Cash Flow Margin | -59.44% | 19.61% | 14.98% | 7.98% | 51.31% | 56.13% | Upgrade
|
| Free Cash Flow Per Share | -4.82 | 1.89 | 1.62 | 0.83 | 4.36 | 5.65 | Upgrade
|
| Cash Interest Paid | 1,554 | 3,830 | 3,484 | 3,536 | 2,772 | 4,239 | Upgrade
|
| Cash Income Tax Paid | 371.58 | 403.02 | 300.83 | 613.98 | 379.31 | 1,029 | Upgrade
|
| Levered Free Cash Flow | -5,060 | 8,664 | -2,260 | -1,907 | -10,255 | 773.29 | Upgrade
|
| Unlevered Free Cash Flow | -5,060 | 8,664 | -2,260 | -1,907 | -10,255 | 773.29 | Upgrade
|
| Change in Net Working Capital | 3,816 | -9,741 | 2,358 | 1,959 | 10,703 | 753.43 | Upgrade
|
Source: S&P Capital IQ. Insurance template. Financial Sources.